Abiopharma

Expion360 Reports Second Quarter 2026 Financial and Operational Results

Press Release: AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Mueller Industries, Inc. Announces Retirement of Gary S. Gladstein from the Board of Directors Effective December 31, 2026

Birchtech Announces Results of Voting from Annual Meeting of Stockholders

Uranium Royalty Appoints New Directors to the Board

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)